Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11141306rdf:typepubmed:Citationlld:pubmed
pubmed-article:11141306lifeskim:mentionsumls-concept:C0682458lld:lifeskim
pubmed-article:11141306lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:11141306lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:11141306lifeskim:mentionsumls-concept:C0024264lld:lifeskim
pubmed-article:11141306lifeskim:mentionsumls-concept:C0680730lld:lifeskim
pubmed-article:11141306lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:11141306lifeskim:mentionsumls-concept:C0870883lld:lifeskim
pubmed-article:11141306lifeskim:mentionsumls-concept:C0649962lld:lifeskim
pubmed-article:11141306lifeskim:mentionsumls-concept:C1148554lld:lifeskim
pubmed-article:11141306pubmed:issue1lld:pubmed
pubmed-article:11141306pubmed:dateCreated2001-2-15lld:pubmed
pubmed-article:11141306pubmed:abstractTextA sensitive precolumn derivatization method has been developed to measure the 5'-triphosphate of 2'-beta-fluoro-2',3'-dideoxyadenosine (F-ddA, lodenosine), a new anti-HIV drug, in human lymphocytes by HPLC using fluorescence detection. Reaction of chloroacetaldehyde with F-ddA triphosphate in extracts from human lymphocytes produces a highly fluorescent etheno adduct. This derivative is then separated and quantitated by reverse-phase paired-ion chromatography. Degradation of natural nucleic acid ribosides, such as ATP, using periodate oxidation simplifies the chromatogram and minimizes interference with detection of the target analyte. This method, modeled using cultured MOLT-4 T-lymphocytes, achieves a linear detector response for peak area measurements over the range 2.5 to 22.5 pmol (50-450 nM using 50 microl sample). Analyte recovery is greater than 90%, and the method achieves a limit of detection and limit of quantitation of 1.4 and 2.5 pmol per HPLC injection (50 microl sample containing cellular extract from 2.5 x 10(6) cells), respectively. Application of this method to measure F-ddATP in peripheral blood mononuclear cells from HIV-infected patients treated with F-ddA at 3.2 mg/kg twice daily for 22 days shows F-ddATP levels which range from 1.5 to 3.5 pmol/10(6) cells.lld:pubmed
pubmed-article:11141306pubmed:languageenglld:pubmed
pubmed-article:11141306pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11141306pubmed:citationSubsetIMlld:pubmed
pubmed-article:11141306pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11141306pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11141306pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11141306pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11141306pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11141306pubmed:statusMEDLINElld:pubmed
pubmed-article:11141306pubmed:monthJanlld:pubmed
pubmed-article:11141306pubmed:issn0003-2697lld:pubmed
pubmed-article:11141306pubmed:authorpubmed-author:KelleyJ AJAlld:pubmed
pubmed-article:11141306pubmed:authorpubmed-author:YarchoanRRlld:pubmed
pubmed-article:11141306pubmed:authorpubmed-author:WellerKKlld:pubmed
pubmed-article:11141306pubmed:authorpubmed-author:ZhangHHlld:pubmed
pubmed-article:11141306pubmed:authorpubmed-author:ECKGGlld:pubmed
pubmed-article:11141306pubmed:authorpubmed-author:LietzauJJlld:pubmed
pubmed-article:11141306pubmed:authorpubmed-author:FordHHJrlld:pubmed
pubmed-article:11141306pubmed:authorpubmed-author:MalinowskiNNlld:pubmed
pubmed-article:11141306pubmed:authorpubmed-author:KavlickM FMFlld:pubmed
pubmed-article:11141306pubmed:copyrightInfoCopyright 2001 Academic Press.lld:pubmed
pubmed-article:11141306pubmed:issnTypePrintlld:pubmed
pubmed-article:11141306pubmed:day1lld:pubmed
pubmed-article:11141306pubmed:volume288lld:pubmed
pubmed-article:11141306pubmed:ownerNLMlld:pubmed
pubmed-article:11141306pubmed:authorsCompleteYlld:pubmed
pubmed-article:11141306pubmed:pagination52-61lld:pubmed
pubmed-article:11141306pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11141306pubmed:meshHeadingpubmed-meshheading:11141306...lld:pubmed
pubmed-article:11141306pubmed:meshHeadingpubmed-meshheading:11141306...lld:pubmed
pubmed-article:11141306pubmed:meshHeadingpubmed-meshheading:11141306...lld:pubmed
pubmed-article:11141306pubmed:meshHeadingpubmed-meshheading:11141306...lld:pubmed
pubmed-article:11141306pubmed:meshHeadingpubmed-meshheading:11141306...lld:pubmed
pubmed-article:11141306pubmed:meshHeadingpubmed-meshheading:11141306...lld:pubmed
pubmed-article:11141306pubmed:meshHeadingpubmed-meshheading:11141306...lld:pubmed
pubmed-article:11141306pubmed:meshHeadingpubmed-meshheading:11141306...lld:pubmed
pubmed-article:11141306pubmed:meshHeadingpubmed-meshheading:11141306...lld:pubmed
pubmed-article:11141306pubmed:meshHeadingpubmed-meshheading:11141306...lld:pubmed
pubmed-article:11141306pubmed:meshHeadingpubmed-meshheading:11141306...lld:pubmed
pubmed-article:11141306pubmed:meshHeadingpubmed-meshheading:11141306...lld:pubmed
pubmed-article:11141306pubmed:meshHeadingpubmed-meshheading:11141306...lld:pubmed
pubmed-article:11141306pubmed:year2001lld:pubmed
pubmed-article:11141306pubmed:articleTitleFluorometric determination of 2'-beta-fluoro-2',3'-dideoxyadenosine 5'-triphosphate, the active metabolite of a new anti-human immunodeficiency virus drug, in human lymphocytes.lld:pubmed
pubmed-article:11141306pubmed:affiliationLaboratory of Medical Chemistry, Division of Basic Sciences, National Institutes of Health, Bethesda, Maryland 20892, USA.lld:pubmed
pubmed-article:11141306pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11141306pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:11141306pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed